MacuLogix, Inc., an Hummelstown, PA-based developer of a tool for the early detection and tracking of age-related macular degeneration (AMD), raised $3.6m in Series A funding.
Backers included Berwind Private Equity, Roche Venture Fund, Life Sciences Greenhouse of Central Pennsylvania, and Ben Franklin Technology Partners of Central and Northern Pennsylvania.
The company intends to use funds to accelerate manufacturing and commercial sales of the MacuLogix’ AdaptDx™, which will provide doctors with a functional diagnostic to intervene at the earliest possible time to prevent vision loss and improve quality of life.
The tool has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD.
It is not currently cleared for sale as a diagnostic.
The company is led by John G. Edwards, CEO.